Metabolism open · 2026
Evaluation of the anti-hyperglycemic and anti-dyslipidemic potential of the hydroethanolic extract of Graptophyllum pictum (Acanthaceae) aerial parts in streptozotocin-nicotinamide-induced diabetic Wistar rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Pradeep, Mishra Garima
Аннотация
CONTEXT: Diabetes is a chronic metabolic disorder that affects approximately 537 million people worldwide. Modern diabetic therapies include adverse effects and are expensive. Scientists are often exploring affordable natural treatments with little or no side effects. Graptophyllum pictum was chosen for the study due to its traditional claim of reducing blood glucose levels and established glucosidase inhibitory action.
OBJECTIVE: In this experimental work, the hydroethanolic extract of G. pictum (L.) Griff aerial part was evaluated for hypoglycemic, antihyperglycemic, antidyslipidemic, and protective effects on liver enzymes in streptozotocin (STZ)-nicotinamide (NA)-induced diabetic Wistar rats.
METHODS: Diabetes was induced in Wistar rats using an intraperitoneal injection of STZ (60 mg/kg) just 15 min after injecting NA (120 mg/kg). Glibenclamide (10 mg/kg) as a standard and hydroethanolic extract (250 and 500 mg/kg) were used for the treatment of diabetic rats. Throughout the study (21 days), normal and diabetic control animals were given only normal saline (5 mL/kg, p.o).
RESULTS: The findings revealed that hydroethanolic extract did not have any significant hypoglycemic activity but had a significant effect (P < 0.001) when compared to the diabetic control group on lowering blood glucose levels (106 ± 1.41 versus 322.16 ± 2.08) and body weight of diabetic rats, as well as significantly restoring lipid profile (105.83 ± 1.77 versus 195.33 ± 1.49, P < 0.001, total cholesterol; 128.33 ± 1.38 versus 204.5 ± 1.94, P < 0.01, triglycerides; 42.66 ± 1.32 versus 94.83 ± 1.77, P < 0.01, low-density lipoprotein cholesterol; 29.5 ± 0.42 versus 41.83 ± 0.99, P < 0.01, very low-density lipoprotein cholesterol; 29 ± 2.13 versus 15.5 ± 0.84, P < 0.01, high-density lipoprotein cholesterol) and liver enzymes (166.5 ± 1.72 versus 314.83 ± 1.71, P < 0.001, aspartate aminotransferase; 114 ± 1.98 versus 173.5 ± 1.52, P < 0.01, alanine aminotransferase).
CONCLUSION: Conclusively, results from our study on G. pictum hydroethanolic extract validates its use as an anti-diabetic agent and may offer a new perspective on type 2 diabetic therapy.
OBJECTIVE: In this experimental work, the hydroethanolic extract of G. pictum (L.) Griff aerial part was evaluated for hypoglycemic, antihyperglycemic, antidyslipidemic, and protective effects on liver enzymes in streptozotocin (STZ)-nicotinamide (NA)-induced diabetic Wistar rats.
METHODS: Diabetes was induced in Wistar rats using an intraperitoneal injection of STZ (60 mg/kg) just 15 min after injecting NA (120 mg/kg). Glibenclamide (10 mg/kg) as a standard and hydroethanolic extract (250 and 500 mg/kg) were used for the treatment of diabetic rats. Throughout the study (21 days), normal and diabetic control animals were given only normal saline (5 mL/kg, p.o).
RESULTS: The findings revealed that hydroethanolic extract did not have any significant hypoglycemic activity but had a significant effect (P < 0.001) when compared to the diabetic control group on lowering blood glucose levels (106 ± 1.41 versus 322.16 ± 2.08) and body weight of diabetic rats, as well as significantly restoring lipid profile (105.83 ± 1.77 versus 195.33 ± 1.49, P < 0.001, total cholesterol; 128.33 ± 1.38 versus 204.5 ± 1.94, P < 0.01, triglycerides; 42.66 ± 1.32 versus 94.83 ± 1.77, P < 0.01, low-density lipoprotein cholesterol; 29.5 ± 0.42 versus 41.83 ± 0.99, P < 0.01, very low-density lipoprotein cholesterol; 29 ± 2.13 versus 15.5 ± 0.84, P < 0.01, high-density lipoprotein cholesterol) and liver enzymes (166.5 ± 1.72 versus 314.83 ± 1.71, P < 0.001, aspartate aminotransferase; 114 ± 1.98 versus 173.5 ± 1.52, P < 0.01, alanine aminotransferase).
CONCLUSION: Conclusively, results from our study on G. pictum hydroethanolic extract validates its use as an anti-diabetic agent and may offer a new perspective on type 2 diabetic therapy.